House Panel Directs DEA to Act on Unregulated Cannabinoid Products

The House Appropriations Committee is pressing federal drug enforcement to move against the unregulated cannabinoid market before a broader federal reckoning arrives in November, directing the DEA to take enforcement action against products that “threaten consumer safety” — and to report back to Congress on what resources it needs to do so.

The committee is set to approve a report attached to the fiscal year 2027 spending bill covering Commerce, Justice, Science, and Related Agencies at its markup session on May 13, 2026. The directive targets the “proliferation of Federally unregulated ingestible, inhalable, and topical products that contain intoxicating cannabinoids” — language aimed squarely at the delta-8, THCA flower, and synthetic cannabinoid products that have filled vape shops, gas stations, and online marketplaces since the 2018 Farm Bill opened the legal hemp market.

What the Directive Requires

Under the committee’s report language, the DEA must act — in coordination with the FDA’s Office of Inspections and Investigations — against sellers whose products fail to meet the federal hemp definition and pose consumer safety risks. The directive covers two overlapping legal standards: the hemp definition established by the 2018 Farm Bill and the narrower definition enacted in November 2025, which takes full effect on November 12, 2026.

The DEA would also be required to report to Congress on enforcement efforts and any additional resources it needs within 90 days of the bill becoming law. That accountability mechanism matters: it gives appropriators a direct read on whether the agency is actually deploying resources against the unregulated market rather than waiting for the November deadline to resolve the problem on its own.

The committee’s directive frames its action as enforcement of existing law, not new rulemaking. Most of the synthetic and semi-synthetic cannabinoid products on the market today — including HHC, delta-8 THC manufactured via chemical conversion, and THCA flower sold across state lines — already fall outside the hemp framework under the DEA’s own legal interpretation, even before the November 2026 restrictions kick in.

The Enforcement Gap Congress Is Trying to Close

The backdrop is a years-long gap between what federal law permits and what’s actually on shelves. The 2018 Farm Bill legalized hemp by capping delta-9 THC at 0.3 percent by dry weight, but that definition left space for a multibillion-dollar market in converted and synthetic cannabinoids that mimic marijuana’s effects. Products derived through chemical conversion — CBD converted into delta-8 THC via isomerization, for example — are not naturally produced by the hemp plant, and the DEA has consistently maintained they remain controlled substances regardless of what the starting plant material was.

The agency reaffirmed that position in a May 4, 2026 Federal Register action, separately codifying HHC as a Schedule I controlled substance under its own drug code and stating that cannabinoids produced through chemical conversion do not qualify as hemp derivatives under the Farm Bill. The Ninth Circuit has pushed back on that interpretation in prior rulings, holding that the Farm Bill’s plain text covers all hemp derivatives. But the committee’s enforcement directive sidesteps that judicial dispute by grounding its request in both the 2018 Farm Bill standard and the November 2025 amendments — amendments that Congress enacted specifically to close what lawmakers called a loophole.

The November 2025 legislation substantially narrowed the hemp definition: it shifted the THC threshold from delta-9 only to total THC including THCA, excluded cannabinoids synthesized outside the plant, and capped finished hemp-derived products at a combined 0.4 milligrams of total THC per container. Industry groups estimate that limit effectively disqualifies more than 90 percent of the current intoxicating hemp market. Texas has moved state-level enforcement against hemp-derived THC products already, with litigation still pending over the scope of state authority to act before November.

What Else Is in the Same Spending Bill

The CJS bill carries several other provisions with direct consequences for the cannabis industry. An anti-rescheduling rider blocks federal officials from taking any further steps toward moving cannabis to a lower drug schedule — a recurring feature of Republican-led appropriations battles. The bill also includes an updated version of the longstanding provision protecting state medical cannabis programs, prohibiting federal funds from being used to interfere with state-licensed medical marijuana operations.

The report also directs the Justice Department to deploy anti-money-laundering resources against Chinese-connected illegal marijuana grow operations inside the U.S. And the Bureau of Prisons would receive $8.5 million to launch a wastewater surveillance pilot at a minimum of six federal correctional institutions, monitoring for synthetic cannabinoids alongside fentanyl and other drugs.

For the regulated cannabis industry, the significant signal in the committee’s action is what the enforcement directive doesn’t say: nothing softens the November 2026 deadline, and nothing tells the DEA to wait. The committee is directing the agency to act against existing violations of existing law, now. For licensed hemp and cannabis operators who have watched the unregulated market undercut them for years, that’s the directive they’ve been asking for. Whether the DEA actually moves before November — and with what enforcement resources — is what the 90-day report requirement is designed to force into the open.